This is of great clinical significance, as PD-1 and PD-L1 inhibitor first-line monotherapy is currently limited to patients with high PD-L1 expression, while most patients, such as those with metastatic NSCLC, have tumors with low or negative PD-L1 expression [43]. Here, PDCD1 is linked to non-small cell lung carcinoma.